The Military Hospital in Padova hosted a few weeks ago the 4th General Assembly of the Partners of the "http://eurocondor.eu/" EUROCONDOR EU-funded research project, coordinated by Vall d'Hebron Research Institute (VHIR), headed by Dr. Rafael Simó, leader of the Diabetes and Metabolism group.This EUROCONDOR project aims to improve the lives of people with diabetes by developing a new treatment of diabetic retinopathy, aneurodegenerative disease of the eye. The therapeutic strategy of the EUROCONDOR project is based on neuroprotection to prevent or arrest retinal neurodegeneration in early stages of the disease. It is a prospective and randomized study in 450 type 2 diabetic patients of two neuroprotectors therapeutic agents (somatostatin and brimonidine), administered topically through eye drops.During this meeting, in which participated 37 researchers, there has been a review of the basic research that supports this clinical trial that started in February 2013 and a depth debate about the whole clinical protocol and the way of implementing it in all the participant countries.Much emphasis has been done in the safety topics, possible adverse effects, therapeutic fulfillment, and analysis of efficiency and dissemination of the results.